caa a22 4500 477128785 CHVBK 20180405111657.0 cr unu---uuuuu 170330e19971101xx s 000 0 eng 10.1023/A:1018404110180 doi (NATIONALLICENCE)springer-10.1023/A:1018404110180 Risk for endometrial cancer following breast cancer: a prospective study in Sweden [Elektronische Daten] [Hans-Olov Adami, Reinhold Bergström, Elisabete Weiderpass, Ingemar Persson, Lotti Barlow, Joseph McLaughlin] The risk for endometrial cancer among women with breast cancer might increase following use of tamoxifen, recently classified as a carcinogen of the human endometrium. However, the strength of the association remains uncertain and it is unknown whether use of this drug - widely prescribed in Sweden since the mid-1980s - has had any measurable effect at the population level. We analyzed all cases of breast cancer (n = 131,614) detected in the nationwide Swedish Cancer Registry in 1958-93. Incident cases of endometrial cancer during follow-up were identified also through the Cancer Registry. Standardized incidence ratios (SIR) and their 95 percent confidence intervals(CI) were computed by use of nationwide rates of endometrial cancer, adjusted for age and calendar year. During follow-up of up to 35 years of the breast cancer cohort, 803 incident endometrial cancers were identified, yielding an overall SIR of 1.58 (CI = 1.47-1.70). In univariate analyses, there was no increase in SIR in recent years. However, the excess risk increased linearly with increasing age at breast cancer diagnosis (P trend < 0.0001) and decreased markedly with longer follow-up (P trend < 0.0001). A multivariate regression analysis, with adjustment for age and year of follow-up, revealed no increased risk for subsequent endometrial cancer among breast cancer cases diagnosed more recently (P trend = 0.19); compared with the period 1958-63,the risk estimate in the last time period (1989-93) was 0.72 (CI =0.51-1.01). We conclude that the risk for endometrial cancer following breast cancer has not increased over time in Sweden. Chapman and Hall, 1997 Breast cancer nationallicence endometrial cancer nationallicence Sweden nationallicence tamoxifen nationallicence women nationallicence Adami Hans-Olov Department of Medical Epidemiology, Karolinska Institutet, Stockholm, Sweden aut Bergström Reinhold Department of Medical Epidemiology, Karolinska Institutet, Stockholm, Sweden aut Weiderpass Elisabete Department of Medical Epidemiology, Karolinska Institutet, Stockholm, Sweden aut Persson Ingemar Department of Medical Epidemiology, Karolinska Institutet, Stockholm, Sweden aut Barlow Lotti Epidemiologic Center, National Board of Health and Welfare, Stockholm, Sweden aut McLaughlin Joseph International Epidemiology Institute, RockvilleA, USA aut Cancer Causes & Control Kluwer Academic Publishers 8/6(1997-11-01), 821-827 0957-5243 8:6<821 1997 8 10552 https://doi.org/10.1023/A:1018404110180 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1023/A:1018404110180 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Adami Hans-Olov Department of Medical Epidemiology, Karolinska Institutet, Stockholm, Sweden aut NATIONALLICENCE 700 1- Bergström Reinhold Department of Medical Epidemiology, Karolinska Institutet, Stockholm, Sweden aut NATIONALLICENCE 700 1- Weiderpass Elisabete Department of Medical Epidemiology, Karolinska Institutet, Stockholm, Sweden aut NATIONALLICENCE 700 1- Persson Ingemar Department of Medical Epidemiology, Karolinska Institutet, Stockholm, Sweden aut NATIONALLICENCE 700 1- Barlow Lotti Epidemiologic Center, National Board of Health and Welfare, Stockholm, Sweden aut NATIONALLICENCE 700 1- McLaughlin Joseph International Epidemiology Institute, RockvilleA, USA aut NATIONALLICENCE 773 0- Cancer Causes & Control Kluwer Academic Publishers 8/6(1997-11-01), 821-827 0957-5243 8:6<821 1997 8 10552 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer